Regis Kreitchmann1, Stein Schalkwijk2, Brookie Best3, Jiajia Wang4, Angela Colbers2, Alice Stek5, David Shapiro4, Tim Cressey6,7,8, Mark Mirochnick9, David Burger2. 1. HIV Research Department, Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil. 2. Departments of Pharmacy and Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands. 3. University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences & Department of Pediatrics, University of California San Diego/Rady Children's Hospital-San Diego, San Diego, CA, USA. 4. Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 5. Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles, CA, USA. 6. Department of Medical Technology, Faculty of Associated Medical Sciences, PHPT/IRD 174, Chiang Mai University, Chiang Mai, Thailand. 7. Department of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 8. Department of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, UK. 9. Boston University School of Medicine, Boston, MA, USA.
Abstract
BACKGROUND: Limited data exist on efavirenz pharmacokinetics in HIV-positive pregnant women and neonatal washout. METHODS: HIV-infected pregnant women receiving 600 mg efavirenz once daily had intensive steady-state 24-h pharmacokinetics profiles during the second trimester (2T), third trimester (3T) and 6-12 weeks postpartum (PP). Maternal and umbilical cord blood samples were drawn at delivery and neonatal washout pharmacokinetics were determined. Therapeutic targets were the estimated 10th percentile efavirenz area under the concentration-time curve (AUC) in non-pregnant historical controls (40.0 μg•h/ml) and a trough concentration (C24 h) of 1 μg/ml. Data were prospectively collected within two trials: IMPAACT P1026s (United States) and PANNA (Europe). RESULTS: Among 42 women studied, 15, 42 and 40 had efavirenz pharmacokinetic data available in 2T, 3T and PP, respectively. Median (range) 3T age 33 (20.7-43.5) years, weight 74 (50-132) kg and gestational age 33.4 (28.4-37.9 weeks). Efavirenz AUC during the 3T (60 μg•h/ml) was similar to that reported in non-pregnant adults (58 μg•h/ml). Exposure in the 2T was lower, but within the 0.80-1.25 range. C24 concentrations during pregnancy were lower compared to historical controls on 600 mg efavirenz, however, they were similar to the C24 concentrations after equally potent dose of 400 mg efavirenz. Cord blood/maternal plasma concentration ratio (range) was 0.67 (0.36-0.95). Among 23 infants with washout data available, median (interquartile range) elimination half-life was 65.6 h (40.6-129). HIV RNA viral loads at delivery were <400 and <50 copies/ml for 96.7% and 86.7% of women, respectively. In 3T and PP, respectively, 8/41 (19%) and 6/40 (15%) had AUC below target; 7/41 (17%) and 3/39 (8%) had C24 below target. CONCLUSIONS: Efavirenz exposure was similar during pregnancy compared with PP, C24 was in line with C24 after 400 mg equipotent efavirenz dosing. Efavirenz readily crossed the placenta and infant elimination half-life was over twice that of maternal participants. Clincaltrials.gov identifiers: NCT00825929 and NCT00042289.
BACKGROUND: Limited data exist on efavirenz pharmacokinetics in HIV-positive pregnant women and neonatal washout. METHODS:HIV-infected pregnant women receiving 600 mg efavirenz once daily had intensive steady-state 24-h pharmacokinetics profiles during the second trimester (2T), third trimester (3T) and 6-12 weeks postpartum (PP). Maternal and umbilical cord blood samples were drawn at delivery and neonatal washout pharmacokinetics were determined. Therapeutic targets were the estimated 10th percentile efavirenz area under the concentration-time curve (AUC) in non-pregnant historical controls (40.0 μg•h/ml) and a trough concentration (C24 h) of 1 μg/ml. Data were prospectively collected within two trials: IMPAACT P1026s (United States) and PANNA (Europe). RESULTS: Among 42 women studied, 15, 42 and 40 had efavirenz pharmacokinetic data available in 2T, 3T and PP, respectively. Median (range) 3T age 33 (20.7-43.5) years, weight 74 (50-132) kg and gestational age 33.4 (28.4-37.9 weeks). Efavirenz AUC during the 3T (60 μg•h/ml) was similar to that reported in non-pregnant adults (58 μg•h/ml). Exposure in the 2T was lower, but within the 0.80-1.25 range. C24 concentrations during pregnancy were lower compared to historical controls on 600 mg efavirenz, however, they were similar to the C24 concentrations after equally potent dose of 400 mg efavirenz. Cord blood/maternal plasma concentration ratio (range) was 0.67 (0.36-0.95). Among 23 infants with washout data available, median (interquartile range) elimination half-life was 65.6 h (40.6-129). HIV RNA viral loads at delivery were <400 and <50 copies/ml for 96.7% and 86.7% of women, respectively. In 3T and PP, respectively, 8/41 (19%) and 6/40 (15%) had AUC below target; 7/41 (17%) and 3/39 (8%) had C24 below target. CONCLUSIONS:Efavirenz exposure was similar during pregnancy compared with PP, C24 was in line with C24 after 400 mg equipotent efavirenz dosing. Efavirenz readily crossed the placenta and infant elimination half-life was over twice that of maternal participants. Clincaltrials.gov identifiers: NCT00825929 and NCT00042289.
Authors: Bryan A Ward; J Christopher Gorski; David R Jones; Stephen D Hall; David A Flockhart; Zeruesenay Desta Journal: J Pharmacol Exp Ther Date: 2003-04-03 Impact factor: 4.030
Authors: Diane T Holland; Robin DiFrancesco; Judith Stone; Fayez Hamzeh; James D Connor; Gene D Morse Journal: Antimicrob Agents Chemother Date: 2004-03 Impact factor: 5.191
Authors: Ahmed M Elsharkawy; Ulrich Schwab; Brendan McCarron; Alastair D Burt; Ann K Daly; Mark Hudson; Steven Masson Journal: J Clin Virol Date: 2013-06-12 Impact factor: 3.168
Authors: Tim R Cressey; Saik Urien; Edmund V Capparelli; Brookie M Best; Sudanee Buranabanjasatean; Aram Limtrakul; Boonsong Rawangban; Prapan Sabsanong; Jean-Marc Treluyer; Gonzague Jourdain; Alice Stek; Marc Lallemant; Mark Mirochnick Journal: J Antimicrob Chemother Date: 2014-09-25 Impact factor: 5.790
Authors: Regis Kreitchmann; Brookie M Best; Jiajia Wang; Alice Stek; Edmund Caparelli; D Heather Watts; Elizabeth Smith; David E Shapiro; Steve Rossi; Sandra K Burchett; Elizabeth Hawkins; Mark Byroads; Tim R Cressey; Mark Mirochnick Journal: J Acquir Immune Defic Syndr Date: 2013-05-01 Impact factor: 3.731
Authors: L Dickinson; J Amin; L Else; M Boffito; D Egan; A Owen; S Khoo; D Back; C Orrell; A Clarke; M Losso; P Phanuphak; D Carey; D A Cooper; S Emery; R Puls Journal: Clin Pharmacol Ther Date: 2015-07-14 Impact factor: 6.875
Authors: Margaret Lartey; Ernest Kenu; Anyetei Lassey; Michael Ntumy; Vincent Ganu; Miriam Sam; Isaac Boamah; Fizza S Gilani; Hongmei Yang; Gena M Burch; Jennifer Norman; Charles A Peloquin; Awewura Kwara Journal: Clin Ther Date: 2020-08-15 Impact factor: 3.393
Authors: Nadia M Ikumi; Komala Pillay; Tamara Tilburgs; Thokozile R Malaba; Sonwabile Dzanibe; Elizabeth Ann L Enninga; Rana Chakraborty; Mohammed Lamorde; Landon Myer; Saye Khoo; Heather B Jaspan; Clive M Gray Journal: J Infect Dis Date: 2021-12-08 Impact factor: 7.759